Curated News
By: NewsRamp Editorial Staff
October 19, 2026
Quantum BioPharma's Unbuzzd Shows Promise in Alcohol Recovery Study
TLDR
- Quantum BioPharma's Unbuzzd showed a 40.7% faster blood alcohol decline in rapid responders, offering a potential edge in the alcohol recovery market.
- The placebo-controlled study involved 26 healthy adults, with 24 completing both sessions, measuring blood alcohol concentrations and self-rated alertness.
- Quantum BioPharma's Unbuzzd may improve alcohol recovery by reducing blood alcohol levels faster and easing hangover symptoms, though more research is needed.
- Unbuzzd is a formulation from Quantum BioPharma that reportedly speeds alcohol metabolism, but experts caution it does not guarantee sobriety or safe driving.
Impact - Why it Matters
The publication of Unbuzzd's clinical trial results in a mainstream fitness outlet like Men's Fitness brings broader consumer awareness to the alcohol recovery category, which could drive demand for Unbuzzd Wellness products and, by extension, royalty revenue for Quantum BioPharma. For investors, the coverage highlights both the potential of Quantum's pipeline and the rigorous scrutiny such claims face, underscoring the need for larger, independent trials to validate efficacy. As alcohol misuse remains a significant public health issue, any formulation that demonstrably aids recovery could have substantial market impact, making these early findings a noteworthy step in the development of practical harm-reduction tools.
Summary
Quantum BioPharma (NASDAQ: QNTM) is in the spotlight following a Men’s Fitness article by Lakshan Weeraratne that examined clinical trial results for Unbuzzd, an alcohol recovery formulation developed by Quantum and licensed to Unbuzzd Wellness. The article detailed findings from a company-sponsored, placebo-controlled study involving 26 healthy adults, with 24 completing both treatment sessions. Researchers reported significantly lower estimated blood alcohol concentrations at several time points, improved self-rated alertness, and reduced headache severity on certain assessments. Among 17 participants identified as rapid responders, the average percentage decline in estimated blood alcohol during the first 30 minutes was 40.7% greater with Unbuzzd than with placebo.
The Men’s Fitness article also emphasized the study’s limitations, including its small sample size, company sponsorship, and mixed results across broader measures of hangover severity and cognitive impairment. While the findings suggest potential benefits for certain alcohol recovery measures, the article noted that larger, independent clinical trials are needed to confirm the results. It also cautioned that increased alertness does not indicate sobriety or fitness to drive.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., led by industry veterans. Quantum retains ownership of 19.84% of Unbuzzd and is entitled to royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma's Unbuzzd Shows Promise in Alcohol Recovery Study
